Funding profile · NHS primary care software

Anima

A London care enablement platform that has raised at least $14.5 million on the record, against $12 million announced at its Series A. A second Delaware vehicle, named for a mid 2025 financing, points to capital activity that has not been announced.

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reading the filings

1. The filed amount beats the announced amount.Anima’s Series A press release, dated March 19 to 20, 2024, put the round at $12 million (reported as €11 million by two European outlets). The Form D filed months earlier, in November 2023, with a first sale date of October 26, 2023, shows $14,485,002 already sold of a $14,550,003 offering. Either the filing captured money beyond the announced Series A, such as the seed and bridge financing rolled together, or the announced figure understated what had already closed. No amended Form D or later release explains the gap.
2. The filing landed before the press release.The Form D’s first sale date, October 26, 2023, is about five months ahead of the March 2024 Series A announcement. That is a common pattern: institutional money often closes before a company is ready to talk about it publicly.
3. The checks are large and few.Twelve investors accounted for $14.49 million, about $1.2 million each on average. That is consistent with a round led by an institutional fund such as Molten Ventures rather than a wide syndicate of small checks.
4. A second, smaller vehicle points to more recent activity.In October 2025, a Sydecar administered single-deal SPV named “Anima Iris Jun 2025” raised $128,000 from 10 investors, about $12,800 each. The name suggests it was organized around a financing that took place, or was under discussion, around June 2025. No Anima funding announcement from that period was found, and no Form D has been filed directly under Anima’s own name since November 2023.
5. The board named in the filing matches public reporting.Shun Pang (CEO), Rachel Mumford (co-founder and COO) and Inga Deakin (Molten Ventures, which led the Series A) all appear as related persons on the 2023 Form D, alongside a fourth director, Firat Ileri, who has not appeared in press coverage reviewed for this profile.
6. Non-dilutive capital was not found.No NSF, NIH or other federal or UK grant records tied to Anima were found in the searches run for this profile, unlike some peer medtech companies.

Commercial signals

What to watch

• Whether Anima or an affiliated entity files a new Form D that names the round the “Anima Iris” SPV appears to sit alongside.
• Whether the company or press ever reconciles the $12 million announced Series A with the $14.49 million already sold under the same Form D.
• Any MHRA reclassification of Annie from Class I to Class IIa, which would change the compliance cost of the product going forward.
• Named enterprise or ICB contracts, and any published revenue figures.

The Anima story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Junction: Shared investor: Amino Collective. An API that orders lab tests in all 50 US states and standardises data from hundreds of wearables
• Kernal Biologics: Shared investor: Hummingbird Ventures. A Boston company designing messenger RNA that switches on only inside the cells it is aimed at, now building an in vivo CAR T therapy on that idea
• Sensible Biotechnologies: Shared investor: Amino Collective. A platform that grows therapeutic mRNA inside engineered cells instead of making it in a tube
• Liyfe: Similar focus. An AI chatbot built to triage cancer patients' symptoms between office visits, grown out of a medical physicist's telemedicine clinic for breast cancer care

Sources

1. Public recordForm D, Anima Group Inc., CIK 0002000249SEC EDGAR · filed Nov 8, 2023
2. Public recordForm D, Anima Iris Jun 2025 a Series of CGF2021 LLC, CIK 0002092477SEC EDGAR · filed Oct 21, 2025
3. Public recordCompanies House, Continuum Health Limited, 12205370Companies House · accessed Sep 25, 2026
4. Public recordCompanies House, Anima Group Inc., UK establishment BR025788Companies House · opened Jan 4, 2021
5. IndependentExclusive: Anima Targets Better Health Triage With $2.5M SeedCrunchbase News · Apr 2, 2021
6. IndependentHealthcare platform Anima brings Salesforce-like capabilities to clinics, raises $12MTechCrunch · Mar 20, 2024
7. IndependentLondon-based Anima snaps €11 million Series AEU-Startups · Mar 19, 2024
8. IndependentY Combinator alum Anima secures €11M for next-gen clinical operating systemTech Funding News · Mar 19, 2024
9. IndependentUK health service AI tool generated a set of false diagnoses for a patientFortune, Beatrice Nolan · Jul 20, 2025
10. CompanyAnnouncing our Series Aanimahealth.com blog · 2024

Compiled from SEC and Companies House public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Anima. This page is not an offer to sell or a recommendation to buy any security.